ARTICLE | Emerging Company Profile

MabVax: The Bs have it

January 4, 2010 8:00 AM UTC

MabVax Therapeutics Inc. hopes that by focusing on the B cell immune response and going after multiple antigens with its polyvalent therapeutic cancer vaccines, it can improve patient survival where other cancer vaccines have failed.

The company plans to start a Phase II trial of its lead vaccine to treat sarcoma in 1H10...